Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Broadwell Pharmaceutical Co., LTD. Welcome you!

Service hotline:+86-431-85639055

博大伟业
imgboxbg

NEWS CENTER

Your current location:
Homepage
/
/
/
The Rayleigh IV clinical Summary meeting was successfully held

The Rayleigh IV clinical Summary meeting was successfully held

  • Categories:The news
  • Author:2015.9.20
  • Origin:2015.9.20
  • Time of issue:2020-08-24
  • Views:0

(Summary description)    After 17 months of hard work, the phase IV clinical study project of Rayleigh successfully completed the recruitment, enrollment, return visit and statistics of subjects. On September 19, 2015, the project leader, Peking Union Medical College Hospital, and the sponsor, Jilin Great Great Pharmaceutical Co., Ltd. successfully held the "Ruilisheng Phase IV Clinical Summary Meeting" in the National Judge's College Hotel by Yanqi Lake in Beijing.

    Professor Qian Jiaming, President of Gastroenterologist Branch of Chinese Medical Doctor Association and director of gastroenterology Department of Peking Union Medical College Hospital, served as the chairman of the conference and delivered the opening speech.

    Domestic well-known experts in many areas of HP, including China centers for disease control and prevention of infectious disease prevention and control institute vice director professor zhang jz ChengHong professor, Peking University first hospital, wuhan university people's hospital and professor, the first affiliated hospital of nanjing medical university professor rui-hua shi, the first affiliated hospital of zhejiang university professor JiFeng, Peking union medical college hospital professor guo tao 24 experts and scholars, and project bidders - great feats of jilin province pharmaceutical co., LTD., chairman of Mr Duan Chengjun, general manager Mr Xie Wenbo attended the event.

    At this meeting, Mr. Xie Wenbo, the general manager, introduced the company's development history, strategic positioning, products under development and market prospect in detail to the experts and professors attending the meeting. At the same time, Ms. Li Mingru, marketing manager of the company, Shared the product positioning, clinical promotion and application as well as domestic and foreign evidence-based data of Rayleigh.

 

    The data statistical analysis of this project was completed by Professor Wang Li, department of Epidemiology and Health Statistics, Peking Union Medical College. Dr. Tan Bei, project leader of the group, summarized the results of statistical analysis on the background, efficacy and safety of Phase IV clinical study of Rayleigh.

    The results of the main efficacy analysis showed that compared with the conventional triple therapy, the difference of HP eradication rate was as high as 18.4% (P<0.0023), and the difference of HP eradication rate was as high as 19.7% (P<0.0017) in PPS analysis. At the same time, the comparison between the triple therapy and the conventional dose of Relayson tetrad showed that the difference in the incidence of adverse reactions between the two groups was not statistically significant by Fisher's direct probability method. The results of this study further confirmed that, as a chelating dosage form of human trace element zinc and carnosine, the combination of rayleixen and longorder triple anti-HP therapy can significantly improve the eradication rate of HP, and at the same time, it has good safety and tolerability.

    At the meeting, yan chai hospital affiliated to Shanghai jiaotong university, shandong university qilu hospital, medical university first affiliated hospital of zhengzhou, nanchang university first affiliated hospital, wuhan university people's hospital, xiangya hospital, central south university, the first clinical hospital of jilin university, xiamen university affiliated hospital of sun yat-sen, the first affiliated hospital of zhejiang university, the first affiliated hospital of nanjing medical university and so on various sub-center main center researchers summary report, share the relevant experience and experience of each center and rui lai clinical promotion direction put forward many Suggestions; At the same time, the participants communicated and discussed the current situation of HP eradication in China and the problems and challenges faced by the experts, fully affirmed the important value of Relayson in HP eradication, and deeply discussed the direction of recent and future evidence-based research of Relayson.

    To explore rui lai living improve HP eradicate rate of relevant mechanisms, the meeting invited China centers for disease control and prevention of infectious diseases prevention and control of infectious diseases, the deputy director of the exam room, director of the hygiene branch of Chinese medical association member, director of the professor zhang jz, share the imminent "poly pury zinc inhibitory effect of HP and related mechanism to explore" the research ideas and methods of project. The technical route of this study is divided into two steps: The first step is to determine the anti-HP effect (MIC) of Polyprazine by the end of 2015, and to study the interaction between the subinhibitory dose of polyprazine and the common antibiotics used to eradicate HP. The research results provide references for the clinical application of Relissen. The second step is to complete the analysis of bacteriostatic pathways, tar

The Rayleigh IV clinical Summary meeting was successfully held

(Summary description)    After 17 months of hard work, the phase IV clinical study project of Rayleigh successfully completed the recruitment, enrollment, return visit and statistics of subjects. On September 19, 2015, the project leader, Peking Union Medical College Hospital, and the sponsor, Jilin Great Great Pharmaceutical Co., Ltd. successfully held the "Ruilisheng Phase IV Clinical Summary Meeting" in the National Judge's College Hotel by Yanqi Lake in Beijing.

    Professor Qian Jiaming, President of Gastroenterologist Branch of Chinese Medical Doctor Association and director of gastroenterology Department of Peking Union Medical College Hospital, served as the chairman of the conference and delivered the opening speech.

    Domestic well-known experts in many areas of HP, including China centers for disease control and prevention of infectious disease prevention and control institute vice director professor zhang jz ChengHong professor, Peking University first hospital, wuhan university people's hospital and professor, the first affiliated hospital of nanjing medical university professor rui-hua shi, the first affiliated hospital of zhejiang university professor JiFeng, Peking union medical college hospital professor guo tao 24 experts and scholars, and project bidders - great feats of jilin province pharmaceutical co., LTD., chairman of Mr Duan Chengjun, general manager Mr Xie Wenbo attended the event.

    At this meeting, Mr. Xie Wenbo, the general manager, introduced the company's development history, strategic positioning, products under development and market prospect in detail to the experts and professors attending the meeting. At the same time, Ms. Li Mingru, marketing manager of the company, Shared the product positioning, clinical promotion and application as well as domestic and foreign evidence-based data of Rayleigh.

 

    The data statistical analysis of this project was completed by Professor Wang Li, department of Epidemiology and Health Statistics, Peking Union Medical College. Dr. Tan Bei, project leader of the group, summarized the results of statistical analysis on the background, efficacy and safety of Phase IV clinical study of Rayleigh.

    The results of the main efficacy analysis showed that compared with the conventional triple therapy, the difference of HP eradication rate was as high as 18.4% (P<0.0023), and the difference of HP eradication rate was as high as 19.7% (P<0.0017) in PPS analysis. At the same time, the comparison between the triple therapy and the conventional dose of Relayson tetrad showed that the difference in the incidence of adverse reactions between the two groups was not statistically significant by Fisher's direct probability method. The results of this study further confirmed that, as a chelating dosage form of human trace element zinc and carnosine, the combination of rayleixen and longorder triple anti-HP therapy can significantly improve the eradication rate of HP, and at the same time, it has good safety and tolerability.

    At the meeting, yan chai hospital affiliated to Shanghai jiaotong university, shandong university qilu hospital, medical university first affiliated hospital of zhengzhou, nanchang university first affiliated hospital, wuhan university people's hospital, xiangya hospital, central south university, the first clinical hospital of jilin university, xiamen university affiliated hospital of sun yat-sen, the first affiliated hospital of zhejiang university, the first affiliated hospital of nanjing medical university and so on various sub-center main center researchers summary report, share the relevant experience and experience of each center and rui lai clinical promotion direction put forward many Suggestions; At the same time, the participants communicated and discussed the current situation of HP eradication in China and the problems and challenges faced by the experts, fully affirmed the important value of Relayson in HP eradication, and deeply discussed the direction of recent and future evidence-based research of Relayson.

    To explore rui lai living improve HP eradicate rate of relevant mechanisms, the meeting invited China centers for disease control and prevention of infectious diseases prevention and control of infectious diseases, the deputy director of the exam room, director of the hygiene branch of Chinese medical association member, director of the professor zhang jz, share the imminent "poly pury zinc inhibitory effect of HP and related mechanism to explore" the research ideas and methods of project. The technical route of this study is divided into two steps: The first step is to determine the anti-HP effect (MIC) of Polyprazine by the end of 2015, and to study the interaction between the subinhibitory dose of polyprazine and the common antibiotics used to eradicate HP. The research results provide references for the clinical application of Relissen. The second step is to complete the analysis of bacteriostatic pathways, tar

  • Categories:The news
  • Author:2015.9.20
  • Origin:2015.9.20
  • Time of issue:2020-08-24
  • Views:0
Information

    After 17 months of hard work, the phase IV clinical study project of Rayleigh successfully completed the recruitment, enrollment, return visit and statistics of subjects. On September 19, 2015, the project leader, Peking Union Medical College Hospital, and the sponsor, Jilin Great Great Pharmaceutical Co., Ltd. successfully held the "Ruilisheng Phase IV Clinical Summary Meeting" in the National Judge's College Hotel by Yanqi Lake in Beijing.

    Professor Qian Jiaming, President of Gastroenterologist Branch of Chinese Medical Doctor Association and director of gastroenterology Department of Peking Union Medical College Hospital, served as the chairman of the conference and delivered the opening speech.

    Domestic well-known experts in many areas of HP, including China centers for disease control and prevention of infectious disease prevention and control institute vice director professor zhang jz ChengHong professor, Peking University first hospital, wuhan university people's hospital and professor, the first affiliated hospital of nanjing medical university professor rui-hua shi, the first affiliated hospital of zhejiang university professor JiFeng, Peking union medical college hospital professor guo tao 24 experts and scholars, and project bidders - great feats of jilin province pharmaceutical co., LTD., chairman of Mr Duan Chengjun, general manager Mr Xie Wenbo attended the event.

    At this meeting, Mr. Xie Wenbo, the general manager, introduced the company's development history, strategic positioning, products under development and market prospect in detail to the experts and professors attending the meeting. At the same time, Ms. Li Mingru, marketing manager of the company, Shared the product positioning, clinical promotion and application as well as domestic and foreign evidence-based data of Rayleigh.

    The data statistical analysis of this project was completed by Professor Wang Li, department of Epidemiology and Health Statistics, Peking Union Medical College. Dr. Tan Bei, project leader of the group, summarized the results of statistical analysis on the background, efficacy and safety of Phase IV clinical study of Rayleigh.

    The results of the main efficacy analysis showed that compared with the conventional triple therapy, the difference of HP eradication rate was as high as 18.4% (P<0.0023), and the difference of HP eradication rate was as high as 19.7% (P<0.0017) in PPS analysis. At the same time, the comparison between the triple therapy and the conventional dose of Relayson tetrad showed that the difference in the incidence of adverse reactions between the two groups was not statistically significant by Fisher's direct probability method. The results of this study further confirmed that, as a chelating dosage form of human trace element zinc and carnosine, the combination of rayleixen and longorder triple anti-HP therapy can significantly improve the eradication rate of HP, and at the same time, it has good safety and tolerability.

    At the meeting, yan chai hospital affiliated to Shanghai jiaotong university, shandong university qilu hospital, medical university first affiliated hospital of zhengzhou, nanchang university first affiliated hospital, wuhan university people's hospital, xiangya hospital, central south university, the first clinical hospital of jilin university, xiamen university affiliated hospital of sun yat-sen, the first affiliated hospital of zhejiang university, the first affiliated hospital of nanjing medical university and so on various sub-center main center researchers summary report, share the relevant experience and experience of each center and rui lai clinical promotion direction put forward many Suggestions; At the same time, the participants communicated and discussed the current situation of HP eradication in China and the problems and challenges faced by the experts, fully affirmed the important value of Relayson in HP eradication, and deeply discussed the direction of recent and future evidence-based research of Relayson.

    To explore rui lai living improve HP eradicate rate of relevant mechanisms, the meeting invited China centers for disease control and prevention of infectious diseases prevention and control of infectious diseases, the deputy director of the exam room, director of the hygiene branch of Chinese medical association member, director of the professor zhang jz, share the imminent "poly pury zinc inhibitory effect of HP and related mechanism to explore" the research ideas and methods of project. The technical route of this study is divided into two steps: The first step is to determine the anti-HP effect (MIC) of Polyprazine by the end of 2015, and to study the interaction between the subinhibitory dose of polyprazine and the common antibiotics used to eradicate HP. The research results provide references for the clinical application of Relissen. The second step is to complete the analysis of bacteriostatic pathways, targets and drug resistance, and the research results will provide guidance for future drug development, improvement and application strategies.

    This grand meeting not only summarized the clinical research results of Phase IV of Relissen, but also fully confirmed the effectiveness and safety of the combined application of Relissen and conventional triple combination of The core product of Broad Cause to improve the eradication rate of HP. At the same time, the successful convening of this conference has pointed out the direction for future evidence-based research of Riley. Experts attending the meeting agreed that the phase IV research results of Relisson were basically consistent with the actual clinical treatment status at present, and fully affirmed that with the drug resistance rate increasing year by year, Relisson provided safe and effective therapeutic drugs for the clinical treatment of HP-related diseases, and significantly optimized the current treatment plan. At last, The President of the conference, Professor Qian Jiaming expressed his gratitude to all centers for their active participation in the "Rayleigh IV clinical study" and congratulated on the important stage research results achieved by Rayleigh!

Scan the QR code to read on your phone

Jilin Province Great Great Pharmaceutical Co. LTD

Service hotline

+86-431-81158731

CONTACT US

Jilin Province Great Great Pharmaceutical Co. LTD

Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD
Jilin Province Great Great Pharmaceutical Co. LTD

Liaoyuan Production Base: No. 158 Fortune Road, Liaoyuan Economic Development Zone, Jilin Province

Tel:+86-437-6998023

Changchun R&D Center: No. 3786 Juye Street, Jingyue Development Zone, Changchun City, Jilin Province
Tel:+86-431-81158731(Marketing center)

Tel:+86-431-81158756(Research and development center)

Beijing Office: Room 901, Building F, Kaixuan City, 170 Beiyuan Road, Chaoyang District, Beijing
Tel:+86-10-58236233

Medication consultation, feedback on medication adverse reaction, and user complaint telephone:0437-5029815 

NO PUBLIC

Jilin Province Great Great Pharmaceutical Co. LTD

Scan and follow the official official account

Copyright © Jilin Province Great Great Pharmaceutical Co. LTD        吉ICP备20002630号

Website construction:300.cn Changchun   management     

Jilin Province Great Great Pharmaceutical Co. LTD